Certolizumab pegol: an evidence-based review of its place in the treatment of Crohn's disease.

However, at week 12, this benefit was not confirmed, and the difference between the CZP- and placebo-treated groups did not reach statistical significance (27% for CZP 100 mg, 19.4% for CZP 200 mg, and 26.4% for CZP 400 mg vs 23.3% for placebo).

also in 111,027 other papers

In addition, the remission rate at week 4 was higher in the CZP group compared with placebo (20% vs 10%; P <0.05), while a nonsignificant trend in favor of CZP was observed at week 6 and at the combined week 6 and 26 time point ( Table 3 ).

also in 5,406 other papers